# WuXi Biologics

> WuXi Biologics is a VC fund in Wuxi backing Biotechnology and Biopharma. See 8 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Wuxi, China
- Total investments: 8
- Last investment: Jun 2023
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/wuxibiologics
- Website: https://www.wuxibiologics.com/

WuXi Biologics is a open-access technology platform company offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. Across the global biologics research and development community, we enable our partners to find innovative biological treatments for diseasesworldwide.

## Contacts

5 contacts available for WuXi Biologics. Shizune tracks 5 team members at WuXi Biologics. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/wuxi-biologics?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 75% |
| Biopharma | 4 | 50% |
| Medical | 3 | 38% |
| Health Care | 3 | 38% |
| Therapeutics | 3 | 38% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 38% |
| Series B | 2 | 25% |
| Seed | 1 | 13% |
| Convertible Note | 1 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 3 | 38% |
| United States | 3 | 38% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Shaymaa Taieb | Associate Director, upstream Continious Manufacturing | 0 | — |
| Chris Chen | Chief Executive Officer | 2 | — |
| Christine Lu-Wong | Chief Financial Officer & Executive Vice President | 0 | — |
| Weichang Zhou | Chief Technology Officer & Executive Vice President | 0 | — |
| Zhisheng Chen | Chief Executive Officer | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Innolake Biopharm | Innolake Biopharm clinical-stage biotech company with a focus on oncology and autoimmune disease areas. | $14.1M | Series A | Jun 05, 2023 |  |
| Duality Biologics | “To Translate Novel Modality into Reality”. Duality Biologics was founded in January 2020 by Dr. John Zhu, a well-respected investor in the healthcare industry. Duality Bio is committed to developing novel modality drugs to fulfill the unmet medical needs for patients worldwide. Focusing on the oncology and autoimmune diseases, the company hasbuilt a novel internal pipeline including nearly 10 Best-in-Class and First-in-Class bispecific antibody and Antibody-Drug Conjugate (ADC) drugs, of which several drug candidates are in the IND stage. The company has successfully built the next-generation ADC platform with global intellectual property rights. The value of this platform has been validated by a number of drug candidates under development. | $90M | Series B | May 19, 2021 |  |
| Immune-Onc Therapeutics | Immune-Onc Therapeutics is a newly established bio-pharmaceutical company that focuses on developing innovative therapeutic antibodies for cancer treatment. The company applies the latest scientific insights and expertise in drug development to advance novel immuno-oncology products and bring new treatment options to cancer patients. | $73M | Series B | Mar 30, 2021 |  |
| Innolake Biopharm | Innolake Biopharm clinical-stage biotech company with a focus on oncology and autoimmune disease areas. | $45.9M | Seed | Jan 01, 2021 |  |
| Invetx | Invetx is a veterinary therapeutics company that focuses on biopharmaceuticals that bring human biotechnology to animal health.Invetx is building the world’s premier animal health biotechnology innovation platform for protein-based therapeutics.Working closely with best-in-class biotechnology companies, major investors and an extensive networkof industry experts, Invetx is focused on guiding the development of an exciting portfolio of therapies and technologies to deliver the future of animal care.Invetx's network includes experts in both animal and human health, veterinary scientists and clinicians. The company's vision is of a global animal health industry that fully leverages biopharma technologies to deliver dramatically improved health outcomes for pets and farm animal populations. | $10.3M | Series A | Sep 30, 2020 |  |
| Invetx | Invetx is a veterinary therapeutics company that focuses on biopharmaceuticals that bring human biotechnology to animal health.Invetx is building the world’s premier animal health biotechnology innovation platform for protein-based therapeutics.Working closely with best-in-class biotechnology companies, major investors and an extensive networkof industry experts, Invetx is focused on guiding the development of an exciting portfolio of therapies and technologies to deliver the future of animal care.Invetx's network includes experts in both animal and human health, veterinary scientists and clinicians. The company's vision is of a global animal health industry that fully leverages biopharma technologies to deliver dramatically improved health outcomes for pets and farm animal populations. | $15M | Series A | Feb 24, 2020 |  |
| Inhibrx | Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology,orphan diseases, and infectious diseases. Inhibrx has collaborations with Celgene and Bluebird Bio and has received awards from several granting agencies, including NIH, NIAID, and CARB-X. | $40M | Convertible Note | May 21, 2019 |  |
| Duoning Biotech | Duoning Biotech is a serum-free medium and technology developer based on international animal cell culture concepts and process development experience. It is committed to the development and production of serum-free media for new animal cells, while providing formula production and technical support for the biopharmaceutical industry. Withancillary services, the products include basic media such as S1, S2, S3, S3-CD and S4, as well as 2×103 feeds and other feed media based on 2×103 feeds; and customized services. | $14.2M | Series A | Apr 23, 2019 |  |

8 of 8 investments shown.

## Co-investors
- AbCellera — VC Fund, 2 deals together
- [Anterra Capital](https://shizune.co/investors/profile/anterra-capital) — VC Fund, 2 deals together
- [Huagai Capital](https://shizune.co/investors/profile/huagai-capital) — VC Fund, 2 deals together
- [Lilly Asia Ventures](https://shizune.co/investors/profile/lilly-asia-ventures) — VC Fund, 2 deals together
- [Alexandria](https://shizune.co/investors/profile/alexandria-venture) — VC Fund, 1 deal together
- [Ally Bridge Group](https://shizune.co/investors/profile/ally-bridge-group) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does WuXi Biologics invest in?

WuXi Biologics invests primarily in Biotechnology, Biopharma and Medical startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact WuXi Biologics?

Public channels for WuXi Biologics include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at WuXi Biologics?

The team at WuXi Biologics includes Shaymaa Taieb (Associate Director, upstream Continious Manufacturing), Chris Chen (Chief Executive Officer) and Christine Lu-Wong (Chief Financial Officer & Executive Vice President). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co